Spray Venture Partners

Conventus Orthopaedics offers orthopedic and sports medicine services, including surgery, reconstructive procedures, spine surgery, joint replacement, sports medicine, physical therapy, and fracture care. Founded by medical professionals in 2009, the company focuses on less invasive treatments for complex periarticular fractures. It employs advanced nitinol technology to create a platform that delivers robust fixation and reliable repairs. The practice is located in Maple Grove, Minnesota.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacture of side branch stent systems designed for the treatment of coronary bifurcation lesions. Established in 2003, the company focuses on addressing cardiovascular diseases by providing innovative solutions, particularly through its flagship product, the Tryton Side Branch Stent System. This system offers a targeted approach to treating atherosclerotic lesions located in the side branches at bifurcation sites. Tryton Medical distributes its products internationally and also caters to investigational needs within the United States, demonstrating its commitment to advancing cardiovascular care in various markets, including Europe and beyond.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

Solace Therapeutics, Inc. is a medical device company based in Framingham, Massachusetts, that specializes in developing non-surgical, office-based treatments for common bladder disorders, including stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS). The company’s flagship product, the Vesair Bladder Control System, is a lightweight device designed to float within the urinary bladder, effectively addressing involuntary urinary leakage without the need for anesthesia or surgical intervention. Solace Therapeutics aims to enhance patients' quality of life by offering a treatment option that minimizes the side effects often associated with traditional drug and surgical therapies, allowing for a reversible and less intrusive approach to bladder health.

PneumRx, Inc. is a medical device company focused on developing minimally invasive treatments for patients with emphysema. Established in 2004 and based in Mountain View, California, the company is known for its investigational device, the RePneu Lung Volume Reduction Coil, which aims to improve lung function in individuals suffering from this chronic condition.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacture of side branch stent systems designed for the treatment of coronary bifurcation lesions. Established in 2003, the company focuses on addressing cardiovascular diseases by providing innovative solutions, particularly through its flagship product, the Tryton Side Branch Stent System. This system offers a targeted approach to treating atherosclerotic lesions located in the side branches at bifurcation sites. Tryton Medical distributes its products internationally and also caters to investigational needs within the United States, demonstrating its commitment to advancing cardiovascular care in various markets, including Europe and beyond.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

Interlace Medical, Inc. specializes in designing and developing medical devices tailored for interventional gynecologists. The company's primary focus is on creating innovative solutions for office-based procedures that address gynecological diseases and conditions that have historically necessitated surgical intervention in operating rooms. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its advancements, Interlace Medical aims to enhance the efficiency and effectiveness of gynecological treatments, thereby improving patient outcomes.

Facet Solutions, established in 2003 and headquartered in Hopkinton, Massachusetts, specializes in developing surgical devices for treating degenerative spinal disorders. The company's primary product is an anatomic facet joint reconstruction device, designed to provide patients with lumbar spinal stenosis and facet degeneration a motion preservation alternative to lumbar spinal fusion.

Interlace Medical, Inc. specializes in designing and developing medical devices tailored for interventional gynecologists. The company's primary focus is on creating innovative solutions for office-based procedures that address gynecological diseases and conditions that have historically necessitated surgical intervention in operating rooms. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its advancements, Interlace Medical aims to enhance the efficiency and effectiveness of gynecological treatments, thereby improving patient outcomes.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacture of side branch stent systems designed for the treatment of coronary bifurcation lesions. Established in 2003, the company focuses on addressing cardiovascular diseases by providing innovative solutions, particularly through its flagship product, the Tryton Side Branch Stent System. This system offers a targeted approach to treating atherosclerotic lesions located in the side branches at bifurcation sites. Tryton Medical distributes its products internationally and also caters to investigational needs within the United States, demonstrating its commitment to advancing cardiovascular care in various markets, including Europe and beyond.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Leptos Biomedical is a company that specializes in developing innovative neuromodulation therapy solutions for chronic obesity. Founded in 2002 and headquartered in Fridley, Minnesota, the company has created a treatment that operates through the electrical activation of a specific nerve within the autonomic nervous system, utilizing a device similar to a pacemaker. This proprietary approach aims to address the complexities of obesity by targeting the underlying neurological factors contributing to the condition.

Interlace Medical, Inc. specializes in designing and developing medical devices tailored for interventional gynecologists. The company's primary focus is on creating innovative solutions for office-based procedures that address gynecological diseases and conditions that have historically necessitated surgical intervention in operating rooms. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its advancements, Interlace Medical aims to enhance the efficiency and effectiveness of gynecological treatments, thereby improving patient outcomes.

PneumRx, Inc. is a medical device company focused on developing minimally invasive treatments for patients with emphysema. Established in 2004 and based in Mountain View, California, the company is known for its investigational device, the RePneu Lung Volume Reduction Coil, which aims to improve lung function in individuals suffering from this chronic condition.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Interlace Medical, Inc. specializes in designing and developing medical devices tailored for interventional gynecologists. The company's primary focus is on creating innovative solutions for office-based procedures that address gynecological diseases and conditions that have historically necessitated surgical intervention in operating rooms. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its advancements, Interlace Medical aims to enhance the efficiency and effectiveness of gynecological treatments, thereby improving patient outcomes.

Solace Therapeutics, Inc. is a medical device company based in Framingham, Massachusetts, that specializes in developing non-surgical, office-based treatments for common bladder disorders, including stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS). The company’s flagship product, the Vesair Bladder Control System, is a lightweight device designed to float within the urinary bladder, effectively addressing involuntary urinary leakage without the need for anesthesia or surgical intervention. Solace Therapeutics aims to enhance patients' quality of life by offering a treatment option that minimizes the side effects often associated with traditional drug and surgical therapies, allowing for a reversible and less intrusive approach to bladder health.

Facet Solutions, established in 2003 and headquartered in Hopkinton, Massachusetts, specializes in developing surgical devices for treating degenerative spinal disorders. The company's primary product is an anatomic facet joint reconstruction device, designed to provide patients with lumbar spinal stenosis and facet degeneration a motion preservation alternative to lumbar spinal fusion.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Facet Solutions, established in 2003 and headquartered in Hopkinton, Massachusetts, specializes in developing surgical devices for treating degenerative spinal disorders. The company's primary product is an anatomic facet joint reconstruction device, designed to provide patients with lumbar spinal stenosis and facet degeneration a motion preservation alternative to lumbar spinal fusion.

Cotherix is a biopharmaceutical company dedicated to the licensing, development, and commercialization of therapeutic products aimed at treating cardiopulmonary and other chronic diseases. The company's primary focus is on its lead product candidate, Ventavis, which is an inhaled formulation of iloprost. This product serves as an inhalation solution specifically designed for patients suffering from pulmonary arterial hypertension, particularly those experiencing New York Heart Association Class III or IV symptoms. Through its innovative approach, Cotherix seeks to address critical needs in the management of serious respiratory conditions.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.